New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
16:30 EDTCPWR, CLWR, VVUS, S, END, CBOUOn The Fly: Closing Wrap
Stocks on Wall Street finished higher on the day after news out of Washington indicated that compromise on some of the most contentious elements of the fiscal cliff negotiations may be nearing. President Obama and House Speaker John Boehner met for 45 minutes today in Washington after a Washington Post report over the weekend said that the Obama administration had rejected Boehner's most recent offer. The averages opened the session higher and maintained their gains through the day, closing at their highs... ECONOMIC EVENTS: In the U.S., a benchmark for New York state manufacturing, the New York Fed's Empire State Survey, came up negative for a fifth straight month. The December reading, which was forecast to move up to -1.0 from its prior -5.2 level, instead slid to -8.10. In Europe, data showed euro zone exports declined 1.4% in October from the prior month, as imports increased 0.6%. In Asia, Japan elected a new prime minister who has vowed to adopt a large stimulus package, cut interest rates and take other measures to revive growth in the nation's economy... COMPANY NEWS: Sprint (S) struck a deal to acquire the approximately 50% stake in Clearwire (CLWR) it does not already own for $2.97 per share, or $2.2B. Shares of Clearwire traded lower following the news, closing down 47c, or 13.95%, to $2.90, while shares of Sprint were virtually flat on the session, closing up 1c, or 0.18%, to $5.56...MAJOR MOVERS: Among the notable gainers was Caribou Coffee (CBOU), up $3.78,or 30.68%, to $16.10 after agreeing to be acquired by Germany's Joh. A. Benckiser for $16.00 per share in cash, or $340M. Also higher were shares of VIVUS (VVUS), up $1.60, or 13.89%, to $13.07 after a report that prescriptions of the company's weight loss drug Qsymia rose 46% for the weekend ended November 12. Also higher were shares of Compuware (CPWR), up $1.22, or 12.80%, to $10.75 after Elliott Management offered to acquire the company for $11.00 per share in cash, or $2.3B. Among the noteworthy losers was Endeavour (END), which fell $1.11, or 17.62%, to $5.19 after research firm Global Hunter downgraded the stock to Accumulate from Buy and cut its price target on shares to $9 from $13... INDICES: The Dow was up 100.38, or 0.76%, to 13,235.39; the S&P 500 was up 16.78, or 1.19%, to 1,430.36; the Nasdaq was up 39.27, or 1.32%, to 3,010.60.
News For S;CLWR;CBOU;VVUS;CPWR;END From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
11:25 EDTVVUSOrexigen surges after disclosing weight loss drug data, patent news
Shares of Orexigen (OREX) are surging in morning trading after the company disclosed the data from the 25% interim analysis of the LIGHT cardiovascular study when announcing a method of treatment patent was issued for its weight loss drug, Contrave. In the filing, the company disclosed that Contrave demonstrated a statistically significant benefit over placebo for cardiovascular events, including CV death. ANALYST OPINION: The new patent announced today extends protection for Contrave to 2034, analysts at Piper Jaffray stated. The firm thinks the new data could possibly drive a competitive advantage in the U.S. market for Contrave, and enhance probability of approvals outside the U.S. It kept an Overweight rating on Orexigen and raised its price target on the stock to $26 from $16. Meanwhile, Leerink noted the data show a statistically significant Contrave benefit in the intent-to-treat population on MACE, myocardial infarction, stroke, and cardiovascular death. The firm believes the results "present meaningful upside to expectations" and could have a positive impact on the Contrave launch if they are included on the drug's labels. Leerink reiterates an Outperform rating on Orexigen. OTHERS TO WATCH: Other companies that offer weight loss drugs that compete with Contrave include VIVUS (VVUS) and Arena Pharmaceuticals (ARNA). PRICE ACTION: In morning trading, Orexigen shares surged 44.5% to $8.37, VIVUS shares rose 8% to $2.99 and Arena slid 3.5% to $4.13.
March 2, 2015
13:05 EDTSGoogle confirms intent to launch U.S. wireless service, WSJ says
Speaking at an industry conference in Barcelona, Sundar Pichai, who oversees Google’s (GOOG) mobile operating system Android, said the search giant will launch a small scale U.S. wireless service with details to be unveiled in the months ahead, says the Wall Street Journal. Other companies in the space include Verizon (VZ), AT&T (T), Sprint (S) and T-Mobile (TMUS). Reference Link
March 1, 2015
17:44 EDTSSprint, Best Buy announce 'Best Buy One Plan'
Subscribe for More Information
February 27, 2015
14:03 EDTSSprint CEO share purchase shows high commitment, says Wells Fargo
Subscribe for More Information
13:08 EDTSSprint CEO discloses 5.08M share purchase
Subscribe for More Information
February 24, 2015
16:01 EDTVVUSVIVUS reports Q4 EPS (25c), consensus (25c)
Reports Q4 revenue $21.7M, consensus $20.01M.
06:35 EDTSSprint downgraded to Sell from Neutral at BTIG

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use